68280 Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices 

TABLE 2—OVERVIEW OF DATA COLLECTION PROCESS FOR ALONE AND TOGETHER CONDITIONS

Steps 

Viewing condition 

Alone Together 

1 ........................... Consumer completes prequestionnaire .................................. Consumer and spouse complete prequestionnaire separately (spouse completes selected measures). 

2 ........................... Consumer views advertising stimuli alone .............................. Consumer and spouse view advertising stimuli together. 

3 ........................... Break ....................................................................................... Couples engage in a 5-minute semistructured conversation 

related to the advertising stimuli. 

4 ........................... Consumer completes postquestionnaire ................................. Consumer and spouse complete postquestionnaire separately (spouse completes selected measures). 

To examine differences between 

experimental conditions, we will 

conduct inferential statistical tests such 

as analysis of variance. With the sample 

size described below, we will have 

sufficient power to detect small-tomedium sized effects in the main study. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN 1

Activity Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total 

hours 

Pretesting 

Number to complete the screener ................................................... 700 1 700 0.08 

(5 minutes) 

56 

Number of completes ....................................................................... 120 1 120 1 120 

Main study 

Number to complete the screener ................................................... 4,060 1 4,060 0.08 

(5 minutes) 

325 

Number of completes ....................................................................... 792 1 792 1 792 

Total .......................................................................................... ........................ ........................ ........................ ........................ 1,293 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Dated: November 7, 2014. 

Leslie Kux, 

Assistant Commissioner for Policy. 

[FR Doc. 2014–26918 Filed 11–13–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2014–N–1617] 

Blood Products Advisory Committee; 

Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

amendment to the notice of the meeting 

of the Blood Products Advisory 

Committee. This meeting was 

announced in the Federal Register of 

October 22, 2014. The amendment is 

being made to reflect a change in the 

Agenda portion of the document. There 

are no other changes. 

FOR FURTHER INFORMATION CONTACT: 

Bryan Emery or Joanne Lipkind, Center 

for Biologics Evaluation and Research, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 71, Rm. 

6132, Silver Spring, MD 20993, 240– 

402–8054 or 240–402–8129, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

Agency’s Web site at http://

www.fda.gov/AdvisoryCommittees/

default.htm and scroll down to the 

appropriate advisory committee meeting 

link, or call the advisory committee 

information line to learn about possible 

modifications before coming to the 

meeting. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of October 22, 2014 (79 

FR 63131), FDA announced that a 

meeting of the Blood Products Advisory 

Committee would be held on December 

2 and 3, 2014. On page 63131, in the 

third column, the Agenda portion of the 

document is changed to read as follows: 

Agenda: On December 2, 2014, the 

Committee will meet in open session to 

hear scientific data related to 

reconsideration of the current blood 

donor deferral policy for men who have 

had sex with another man (MSM) even 

one time since 1977. The Committee 

will be presented with an update on the 

November 13, 2014, meeting of the U.S. 

Department of Health and Human 

Services Advisory Committee on Blood 

and Tissue Safety and Availability 

where the MSM blood donor deferral 

policy will be discussed. In the 

afternoon, the Committee will hear an 

informational presentation on Ebola 

virus, the potential implications for 

blood safety in the United States and 

FDA’s considerations on the collection 

of convalescent plasma for 

investigational use. 

On December 3, 2014, the Blood 

Products Advisory Committee will be 

seated as a device classification panel. 

In open session, the panel will discuss 

the appropriate device classification of 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices 68281 

blood establishment computer software 

(BECS) and accessories to BECS. Blood 

establishment computer software is 

currently subject to the premarket 

notification (510(k)) provisions of the 

Federal Food, Drug, and Cosmetic Act. 

In the afternoon, an informational 

presentation will be made regarding the 

emergence of chikungunya virus 

infections in the Western Hemisphere 

and potential implications for blood 

transfusion safety. The Committee will 

also hear an informational presentation 

on the first survey of the Rapid Donor 

Surveillance (RapidDOS) project on 

Middle Eastern Respiratory Syndrome 

coronavirus (MERS-CoV) 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: November 10, 2014. 

Jill Hartzler Warner, 

Associate Commissioner for Special Medical 

Programs. 

[FR Doc. 2014–26969 Filed 11–13–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel; Biomonitoring 

Technologies. 

Date: December 3–4, 2014. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Environmental 

Health Sciences, 530 Davis Drive, Keystone 

Building, Research Triangle Park, NC 27709 

(Virtual Meeting). 

Contact Person: Sally Eckert-Tilotta, Ph.D. 

Scientific Review Officer, Nat. Institute of 

Environmental Health Sciences, Office of 

Program Operations, Scientific Review 

Branch, P.O. Box 12233, Research Triangle 

Park, NC 27709, (919) 541–1446, eckertt1@

niehs.nih.gov. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Mitochondrial and Nuclear 

Induced Cross-Talk Perturbations in 

Response to Environmental Insults. 

Date: December 4–5, 2014. 

Time: 8:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Imperial Hotel, 4700 

Emperor Boulevard, Durham, NC 27703. 

Contact Person: Leroy Worth, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research and 

Training, Nat. Institute of Environmental 

Health Sciences, P. O. Box 12233, MD EC– 

30/Room 3171, Research Triangle Park, NC 

27709, 919/541–0670 worth@niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: November 6, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–26909 Filed 11–13–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, PAR12–265 

Ancillary Clinical Studies in Diabetes 

Complications. 

Date: December 11, 2014. 

Time: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: ANN A. JERKINS, Ph.D., 

SCIENTIFIC REVIEW OFFICER, REVIEW 

BRANCH, DEA, NIDDK, NATIONAL 

INSTITUTES OF HEALTH, ROOM 759, 6707 

DEMOCRACY BOULEVARD, BETHESDA, 

MD 20892–5452, 301–594–2242, jerkinsa@

niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS). 

Dated: November 7, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–26908 Filed 11–13–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Library of 

Medicine Special Emphasis Panel; Conflicts 

R01/R21/K01. 

Date: December 10, 2014. 

Time: 12:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Library of Medicine, 6705 

Rockledge Drive, Suite 301, Bethesda, MD 

20817, (Telephone Conference Call). 

Contact Person: Zoe E. Huang, MD, 

Scientific Review Officer, Extramural 

Programs, National Library of Medicine, NIH, 

6705 Rockledge Drive, Suite 301, Bethesda, 

MD 20892–7968, 301–594–4937, huangz@

mail.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES